Additionally, POZEN provided an update on its PA program and the results of its Type A meeting with the FDA last week, wherein the Company indicated that it is currently anticipating an NDA submission in the first half of 2013.About the Co-Rx Study
POZEN Announces PA32540 Provides Superior Antiplatlet Effects Over A Standard Of Care Regimen In A Phase 1 Study (“Co-Rx”)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.